Asset Details
Do you wish to reserve the book?
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series
Do you wish to request the book?
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series
2020
Overview
Thalassemia syndromes are characterized by the inability to produce normal hemoglobin. Ineffective erythropoiesis and red cell transfusions are sources of excess iron that the human organism is unable to remove. Iron that is not saturated by transferrin is a toxic agent that, in transfusion-dependent patients, leads to death from iron-induced cardiomyopathy in the second decade of life. The availability of effective iron chelators, advances in the understanding of the mechanism of iron toxicity and overloading, and the availability of noninvasive methods to monitor iron loading and unloading in the liver, heart, and pancreas have all significantly increased the survival of patients with thalassemia. Prolonged exposure to iron toxicity is involved in the development of endocrinopathy, osteoporosis, cirrhosis, renal failure, and malignant transformation. Now that survival has been dramatically improved, the challenge of iron chelation therapy is to prevent complications. The time has come to consider that the primary goal of chelation therapy is to avoid 24-h exposure to toxic iron and maintain body iron levels within the normal range, avoiding possible chelation-related damage. It is very important to minimize irreversible organ damage to prevent malignant transformation before complications set in and make patients ineligible for current and future curative therapies. In this clinical case-based review, we highlight particular aspects of the management of iron overload in patients with beta-thalassemia syndromes, focusing on our own experience in treating such patients. We review the pathophysiology of iron overload and the different ways to assess, quantify, and monitor it. We also discuss chelation strategies that can be used with currently available chelators, balancing the need to keep non-transferrin-bound iron levels to a minimum (zero) 24 h a day, 7 days a week and the risk of over-chelation.
Publisher
MDPI AG,MDPI
Subject
/ Age
/ Anemia
/ beta-Thalassemia - metabolism
/ beta-Thalassemia - pathology
/ Blood
/ Cardiomyopathies - physiopathology
/ Cardiomyopathies - prevention & control
/ Chelation Therapy - adverse effects
/ Deferoxamine - administration & dosage
/ Deferoxamine - adverse effects
/ Drug Monitoring - instrumentation
/ Enzymes
/ Female
/ Humans
/ Iron
/ Iron Chelating Agents - administration & dosage
/ Iron Chelating Agents - adverse effects
/ Iron Overload - complications
/ Iron Overload - drug therapy
/ Iron Overload - physiopathology
/ Liver
/ Male
/ Nonsteroidal anti-inflammatory drugs
/ Patients
/ Review
/ Serology
/ Transfusion Reaction - blood
